No annual revenue total was found in Jasper Therapeutics, Inc.'s SEC filings.
Jasper Therapeutics, Inc. (JSPR) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $7.3 million in cash and investments and $270,000 in total debt.
Revenue
—
Net income (TTM)
$-31.77M
+65.1% vs year-ago TTM
Operating cash flow (TTM)
$-60.33M
+17.9% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-1.23
+79.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
28.00M
+86.4% vs prior year
Net cash
$7.04M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- JSPR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1788028
- Former names
- Amplitude Healthcare Acquisition Corp (until Sep 29, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | -$36.8M |
| Net income | -$75.8M | -$71.3M | -$64.5M | -$37.7M | -$30.6M |
| Diluted EPS | -$3.95 | -$4.89 | -$6.18 | -$10.33 | — |
| Operating cash flow | -$77.2M | -$62.6M | -$52.1M | -$45.9M | -$33.7M |
| Total assets | $35.8M | $79.9M | $94.9M | $48.4M | $93.7M |
| Total liabilities | $31.6M | $18.2M | $16.5M | $12.4M | $24.1M |
| Stockholders' equity | $4.2M | $61.7M | $78.4M | $36.0M | $69.5M |
| Cash and investments | $28.7M | $71.6M | $86.9M | $38.2M | $84.7M |
| Total debt | $1.2M | $1.8M | $2.8M | $1.1M | $760,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Nov 4, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 5, 2026 | Sep 30, 2026 |
| 8-K/A | Amended current report | Oct 5, 2026 | Jul 16, 2026 |
| 8-K/A | Amended current report | Oct 1, 2026 | Jul 16, 2026 |
All 483 Jasper Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.